{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:17:47Z","timestamp":1791940667832,"version":"4.3.4"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,11,29]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Anfibatide potently inhibits platelet agglutination under static and arterial shear conditions. Anfibatide is efficacious in treating spontaneous or shigatoxin-induced murine models of thrombotic thrombocytopenic purpura.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016000711","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T16:34:09Z","timestamp":1480523649000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":38,"title":["Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"1","author":[{"given":"Liang","family":"Zheng","sequence":"first","affiliation":[{"name":"Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Mao","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Abdelgawwad","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole K.","family":"Kocher","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Li","sequence":"additional","affiliation":[{"name":"Lee\u2019s Pharmaceutical Holdings Limited, Hong Kong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Dai","sequence":"additional","affiliation":[{"name":"Zhaoke Pharmaceutical Co Limited, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[{"name":"Lee\u2019s Pharmaceutical Holdings Limited, Hong Kong, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1680-5295","authenticated-orcid":false,"given":"X. Long","family":"Zheng","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2016,11,22]]},"reference":[{"issue":"6","key":"2019111608335932500_B1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"2019111608335932500_B2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol"},{"issue":"22","key":"2019111608335932500_B3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"key":"2019111608335932500_B4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Zheng","year":"2015","journal-title":"Annu Rev Med"},{"issue":"6855","key":"2019111608335932500_B5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"issue":"5","key":"2019111608335932500_B6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00062752-200209000-00001","article-title":"ADAMTS13 and TTP","volume":"9","author":"Zheng","year":"2002","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"2019111608335932500_B7","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","article-title":"ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions","volume":"100","author":"Dong","year":"2002","journal-title":"Blood"},{"issue":"32","key":"2019111608335932500_B8","doi-asserted-by":"crossref","first-page":"29633","DOI":"10.1074\/jbc.M301385200","article-title":"ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor","volume":"278","author":"Dong","year":"2003","journal-title":"J Biol Chem"},{"issue":"23","key":"2019111608335932500_B9","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111608335932500_B10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/mt.2008.223","article-title":"Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes","volume":"17","author":"Niiya","year":"2009","journal-title":"Mol Ther"},{"issue":"6","key":"2019111608335932500_B11","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111608335932500_B12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111608335932500_B13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann Intern Med"},{"issue":"11","key":"2019111608335932500_B14","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/jth.13137","article-title":"Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13","volume":"13","author":"Plaimauer","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2019111608335932500_B15","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2019111608335932500_B16","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1111\/jth.12934","article-title":"Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use","volume":"13","author":"Cataland","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111608335932500_B17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00921009","article-title":"Steroids, aspirin, and inflammation","volume":"2","author":"Katler","year":"1977","journal-title":"Inflammation"},{"issue":"2-3","key":"2019111608335932500_B18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jsbmb.2010.04.022","article-title":"Steroids: modulators of inflammation and immunity","volume":"120","author":"Chapman","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"2019111608335932500_B19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.23106","article-title":"Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura","volume":"87","author":"Cataland","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111608335932500_B20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1160\/TH10-08-0520","article-title":"Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura","volume":"105","author":"Jilma-Stohlawetz","year":"2011","journal-title":"Thromb Haemost"},{"issue":"17","key":"2019111608335932500_B21","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111608335932500_B22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.transci.2012.03.027","article-title":"The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor nanobody in patients with acquired thrombotic thrombocytopenic purpura","volume":"46","author":"Holz","year":"2012","journal-title":"Transfus Apheresis Sci"},{"issue":"6","key":"2019111608335932500_B23","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111608335932500_B24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1006\/bbrc.1995.1684","article-title":"Functional and sequence characterization of agkicetin, a new glycoprotein Ib antagonist isolated from Agkistrodon acutus venom. offf2p4","volume":"210","author":"Chen","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"2019111608335932500_B25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH13-06-0490","article-title":"Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis","volume":"111","author":"Lei","year":"2014","journal-title":"Thromb Haemost"},{"issue":"15","key":"2019111608335932500_B26","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1111\/bph.13178","article-title":"A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury","volume":"172","author":"Li","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2019111608335932500_B27","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1006\/bbrc.1999.1685","article-title":"Purification, characterization, and cDNA cloning of a new fibrinogenlytic venom protein, Agkisacutacin, from Agkistrodon acutus venom","volume":"265","author":"Cheng","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"2019111608335932500_B28","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/prot.24060","article-title":"Crystal structure of agkisacucetin, a Gpib-binding snake C-type lectin that inhibits platelet adhesion and aggregation","volume":"80","author":"Gao","year":"2012","journal-title":"Proteins"},{"issue":"21","key":"2019111608335932500_B29","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1182\/blood-2014-07-587139","article-title":"Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models","volume":"125","author":"Pickens","year":"2015","journal-title":"Blood"},{"issue":"37","key":"2019111608335932500_B30","doi-asserted-by":"crossref","first-page":"28596","DOI":"10.1074\/jbc.M110.131227","article-title":"Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress","volume":"285","author":"Skipwith","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111608335932500_B31","first-page":"653","article-title":"Purification and characterization of a platelet agglutinating inhibiting protein (Agkisacutacin) from Agkistrodon acutus venom","volume":"32","author":"Cheng","year":"2000","journal-title":"Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai)"},{"issue":"2","key":"2019111608335932500_B32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-0038-1647310","article-title":"Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib","volume":"64","author":"Girma","year":"1990","journal-title":"Thromb Haemost"},{"issue":"39","key":"2019111608335932500_B33","doi-asserted-by":"crossref","first-page":"37777","DOI":"10.1074\/jbc.M305566200","article-title":"Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibalpha binding mechanism induced by snake venom proteins","volume":"278","author":"Maita","year":"2003","journal-title":"J Biol Chem"},{"issue":"7","key":"2019111608335932500_B34","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0969-2126(02)00787-6","article-title":"Structural basis of von Willebrand factor activation by the snake toxin botrocetin","volume":"10","author":"Fukuda","year":"2002","journal-title":"Structure"},{"issue":"10","key":"2019111608335932500_B35","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1172\/JCI26007","article-title":"Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice","volume":"115","author":"Motto","year":"2005","journal-title":"J Clin Invest"},{"key":"2019111608335932500_B36","article-title":"AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura","volume-title":"Blood","author":"Jin"},{"issue":"18","key":"2019111608335932500_B37","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood-2010-02-271957","article-title":"Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice","volume":"116","author":"Huang","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111608335932500_B38","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V97.8.2333","article-title":"Echicetin, a GPIb-binding snake C-type lectin from Echis carinatus, also contains a binding site for IgMkappa responsible for platelet agglutination in plasma and inducing signal transduction","volume":"97","author":"Navdaev","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2019111608335932500_B39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.toxicon.2004.11.017","article-title":"How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects?","volume":"45","author":"Xu","year":"2005","journal-title":"Toxicon"},{"issue":"11","key":"2019111608335932500_B40","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"2019111608335932500_B41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111608335932500_B42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/1\/75\/877414\/advances000711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/1\/75\/877414\/advances000711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T08:34:31Z","timestamp":1573893271000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/1\/75\/15514\/Therapeutic-efficacy-of-the-platelet-glycoprotein"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,11,29]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016000711","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,22]]}}}